Anebulo Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Anebulo Pharmaceuticals Inc cash flow-to-debt ratio. Anebulo Pharmaceuticals Inc (ANEB) has a Cash Flow-to-Debt Ratio of -0.88x as of December 2025, meaning its operating cash flow of $-1.31 Million could theoretically repay -1% of its total liabilities ($1.49 Million) in one year. See Anebulo Pharmaceuticals Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Anebulo Pharmaceuticals Inc (2020–2025)
Cash flow-to-debt ratio of Anebulo Pharmaceuticals Inc from 2020 to 2025. Historical debt coverage capacity for Anebulo Pharmaceuticals Inc across 6 annual periods. Also explore ANEB net asset momentum to track the company's year-over-year net asset growth rate.
Anebulo Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2020–2025)
Anebulo Pharmaceuticals Inc cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Anebulo Pharmaceuticals Inc. For the full cash flow conversion analysis, see ANEB cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -13.02x | $-6.35 Million | $487.69K | ▲ +58.1% |
| 2024 | -31.05x | $-8.09 Million | $260.58K | ▼ -242.7% |
| 2023 | -9.06x | $-9.68 Million | $1.07 Million | ▲ +14.6% |
| 2022 | -10.61x | $-5.44 Million | $512.53K | ▲ +47.4% |
| 2021 | -20.16x | $-4.87 Million | $241.63K | ▼ -2893.3% |
| 2020 | -0.67x | $-150.77K | $223.87K | — |